These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 7772081)

  • 41. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.
    Vega GL; Grundy SM
    JAMA; 1987 Jan; 257(1):33-8. PubMed ID: 3537351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
    Crouse JR; Grundy SM
    Metabolism; 1981 Feb; 30(2):123-8. PubMed ID: 7464561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.
    Dujovne CA; Bays H; Davidson MH; Knopp R; Hunninghake DB; Stein EA; Goldberg AC; Jones P; Lipka LJ; Cuffie-Jackson C
    J Clin Pharmacol; 2001 Jan; 41(1):70-8. PubMed ID: 11144997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
    Seplowitz AH; Smith FR; Berns L; Eder HA; Goodman DS
    Atherosclerosis; 1981 Apr; 39(1):35-43. PubMed ID: 7018502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.
    Davidson MH; Dillon MA; Gordon B; Jones P; Samuels J; Weiss S; Isaacsohn J; Toth P; Burke SK
    Arch Intern Med; 1999 Sep; 159(16):1893-900. PubMed ID: 10493319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebo-controlled trial.
    Isaacsohn JL; Moser M; Stein EA; Dudley K; Davey JA; Liskov E; Black HR
    Arch Intern Med; 1998 Jun; 158(11):1189-94. PubMed ID: 9625398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
    J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism.
    Gaw A; Packard CJ; Lindsay GM; Murray EF; Griffin BA; Caslake MJ; Colquhoun I; Wheatley DJ; Lorimer AR; Shepherd J
    Arterioscler Thromb Vasc Biol; 1996 Feb; 16(2):236-49. PubMed ID: 8620338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.
    Maki KC; Lawless AL; Kelley KM; Dicklin MR; Kaden VN; Schild AL; Rains TM; Marshall JW
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):489-94. PubMed ID: 21297494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A softgel dietary supplement containing esterified plant sterols and stanols improves the blood lipid profile of adults with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled replication study.
    McKenney JM; Jenks BH; Shneyvas E; Brooks JR; Shenoy SF; Cook CM; Maki KC
    J Acad Nutr Diet; 2014 Feb; 114(2):244-249. PubMed ID: 24287284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease.
    Kuo PT; Wilson AC; Kostis JB; Moreyra AE
    Am J Cardiol; 1986 Jun; 57(16):43H-48H. PubMed ID: 3524177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children.
    Guardamagna O; Amaretti A; Puddu PE; Raimondi S; Abello F; Cagliero P; Rossi M
    Nutrition; 2014; 30(7-8):831-6. PubMed ID: 24985000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.